reviewJournal of Medicinal ChemistryJul 12, 2024Closed access

An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)

University of Arizona · AbbVie (United States)

PubMed
Indexed incrossrefpubmed

Abstract

This Perspective is a continuation of our analysis of U.S. FDA-approved small-molecule drugs (1938–2012) containing nitrogen heterocycles. In this study we report drug structure and property analyses of 321 unique new small-molecule drugs approved from January 2013 to December 2023 as well as information about frequency of important heteroatoms such as sulfur and fluorine and key small nitrogen substituents (CN and NO2). The most notable change is an incredible increase in drugs containing at least one nitrogen heterocycle─82%, compared to 59% from preceding decades─as well as a significant increase in the number of nitrogen heterocycles per drug. Pyridine has claimed the #1 high-frequency nitrogen heterocycle…

No related works found for this paper.

Funding